{
    "clinical_study": {
        "@rank": "95863", 
        "arm_group": {
            "arm_group_label": "Partially Hydrolyzed Infant Formula", 
            "arm_group_type": "Experimental", 
            "description": "Fed ad lib."
        }, 
        "brief_summary": {
            "textblock": "This is a non-randomized, single-group, multi-center, two phased study to evaluate formula\n      intolerance."
        }, 
        "brief_title": "Feeding Intolerance in Formula-Fed Infants", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Feeding Intolerance", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Inclusion Criteria for Stage 1:\n\n          -  Singleton full term birth with birth weight of > 2500g.\n\n          -  Infant between 0 and 60 days of age.\n\n          -  Discontinuation of medications that might affect gastrointestinal (GI) tolerance.\n\n          -  Infant is exclusively formula-fed a full-lactose, intact cow milk protein-based\n             infant formula (CMF) for less than 7 days prior to enrollment.\n\n        Inclusion Criteria for Stage 2:\n\n          -  Infant was fed according to protocol in Stage 1 of the study.\n\n          -  Infant was identified as being fussy using the Intolerance Assessment Tool in Stage\n             1.\n\n        Exclusion Criteria:\n\n        Exclusion Criteria for Stage 1:\n\n          -  Chromosomal or major congenital anomalies.\n\n          -  Suspected or known metabolic or physical diseases affecting infant feeding and/or\n             metabolism.\n\n          -  Hospitalization, other than for delivery, prior to enrollment.\n\n          -  Severe uncontrolled eczema, visible bloody stools or milk protein allergy prior to\n             enrollment.\n\n          -  More than 1 substitution of an infant formula other than full-lactose, intact cow\n             milk formula (CMF) since birth.\n\n          -  Use of a prokinetic drug within 7 days before enrollment.\n\n        Exclusion Criteria for Stage 2:\n\n          -  Infant's intolerance symptom was caused by another reason, for example known\n             infection/illness, food allergy, or response to vaccination(s).\n\n          -  Infant has immunization(s) within 3 days of enrollment in Stage 2."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028156", 
            "org_study_id": "DA06"
        }, 
        "intervention": {
            "arm_group_label": "Partially Hydrolyzed Infant Formula", 
            "description": "Commercially available infant formula", 
            "intervention_name": "Partially Hydrolyzed Infant Formula", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Guangdong Women and Children Hospital"
                }, 
                "investigator": {
                    "last_name": "Jielin WU, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu"
                    }, 
                    "name": "Nanjing Maternity and Child Health Care Hospital"
                }, 
                "investigator": {
                    "last_name": "Meiling TONG, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Xin Hua Hospital"
                }, 
                "investigator": {
                    "last_name": "Sheng Xiaoyang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Feeding Intolerance in Formula-Fed Infants: A Non-Randomized, Single-Group, Multi-Center Study", 
        "overall_contact": {
            "email": "kristen.deluca@abbott.com", 
            "last_name": "Kristen DeLuca, MS, RD", 
            "phone": "614-624-5455"
        }, 
        "overall_contact_backup": {
            "email": "bobbie.swearengin@abbott.com", 
            "last_name": "Bobbie Swearengin, RN", 
            "phone": "614-624-7182"
        }, 
        "overall_official": {
            "affiliation": "Abbott Nutrition China", 
            "last_name": "Shirley Li, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Study phase 2; Parent completed questionnaire.", 
            "measure": "Improvement in Fussiness", 
            "safety_issue": "No", 
            "time_frame": "0 to 15 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Study phase 1; Parent completed questionnaire.", 
                "measure": "Diarrhea", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 weeks"
            }, 
            {
                "description": "Study phase 1; Parent completed questionnaire.", 
                "measure": "Constipation", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 weeks"
            }, 
            {
                "description": "Study phase 1; Parent completed questionnaire.", 
                "measure": "Spit-up", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 weeks"
            }, 
            {
                "description": "Study phase 1; Parent completed questionnaire.", 
                "measure": "Gassiness", 
                "safety_issue": "No", 
                "time_frame": "0 to 4 weeks"
            }
        ], 
        "source": "Abbott Nutrition", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott Nutrition", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}